How many investments has Delos Capital made?

Delos Capital has 36 tracked investments, including 2 dated in the last 24 months.

What stage does Delos Capital invest at?

Delos Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What sectors does Delos Capital focus on?

Delos Capital focuses on Biotech, Healthtech, Medical Devices.

Where is Delos Capital located?

Delos Capital is headquartered in Cambridge, US.

Who does Delos Capital co-invest with?

Delos Capital most often shares deals with Ascension Ventures, New Enterprise Associates (NEA), Longitude Capital, among 45 tracked co-investors.

Delos Capital

Venture capital

Cambridge · Seed–Late Stage · 12 people tracked

Also known as DELOS ADVISORS LIMITED · DELOS ADVISORS, INC. · DELOS WEALTH ADVISORS, LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Delos Capital invests in life sciences companies working to address disease and improve patient health. The firm seeks out exceptional science paired with strong founding teams pursuing medical breakthroughs. Drawing on a diverse skill set and a global network, the team supports ground-breaking innovations intended to improve lives worldwide.

Invests inBiotech Healthtech Medical Devices Cambridge China George Town Global United States

Source: firm website, verified Aug 25, 2026.

Stage

Seed–Late Stage

Cambridge, Massachusetts, US

Instruments

Equity

Founded

2014

Last 12 months

1 investment

AUM

$185.6M

VC funds

Tracked investments

Team · 12 people

from the firm's website & public directories

Henry Chen· Managing Partner· Hong Kongin

Henry Chen founded Delos Capital in 2014 and serves as its Managing Partner. He was previously a Partner and Co-Head of Asia at Permira, and earlier spent nine years at Goldman Sachs as a Managing Director and co-head of the General Industrials Group for Asia (ex-Japan), following corporate finance law work at Davis Polk. He has co-founded Curamir Therapeutics and Tulavi Therapeutics and served as CEO and Chairman of Tanvex BioPharma, and holds bachelor's and master's degrees from Harvard University and a JD from Harvard Law School.

h•••@deloscapital.comreveal

Tim Xiao· Partner· Hong Kongin

Partner and founding member of Delos Capital with 16 years in life science advisory and investing; leads investments and sits on or observes boards of numerous biotech and medtech companies. Previously spent seven years in investment banking, most recently at Goldman Sachs.

t•••@deloscapital.comreveal

Eric Huang· Partner, Ph.D.· Boston, Massachusetts, United Statesin

Eric Huang joined Delos Capital as a Senior Advisor in 2020, became an Operating Partner, and transitioned to full-time Partner in 2024. He previously held leadership roles at Moderna Therapeutics, including founding CSO of New Venture Labs, where he conceived the mRNA vaccine platform, and later served as GM and CSO at Moderna Genomics.

e•••@deloscapital.comreveal

Lee Cooper· Managing Director· Cambridge, Massachusettsin

Lee Cooper joined Delos Capital as a Managing Director in 2024, focused on advancing new medicines. He previously invested with Leaps by Bayer, founded a rare-disease genomic diagnostics company as an EIR at RA Capital, and worked on transactions at Moderna Therapeutics. He also lectures on bio-innovation at Tufts and Dartmouth.

l•••@deloscapital.comreveal

Tej Pavoor· Partner· Cambridge, USin

Tej Pavoor joined Delos Capital as a Partner in 2024, focusing on identifying and evaluating life sciences companies. He previously was an Operating Partner at Flagship Pioneering, served as COO of Laronde (now Sail), and spent nearly seven years at Moderna Therapeutics, concluding as SVP overseeing the clinical portfolio; earlier roles included McKinsey and Merck.

t•••@deloscapital.comreveal

Agnes Kwok· Financial Controller· Hong Kongin

Agnes Kwok is the Financial Controller at Delos Capital, based in Hong Kong, where she handles accounting, tax, reporting, and compliance since joining in 2018. She previously worked as Vice President in the Finance and Corporate Tax team at Bank of America Merrill Lynch for eight years and began her career at Ernst & Young focusing on banking, financial services, and asset management. She holds a BBA (Hons) in Accountancy from City University of Hong Kong and is a HK Certified Public Accountant and a member of The Institute of Chartered Accountants in England and Wales.

Andrea Lok· Executive Assistant· Hong Kongin

Andrea Lok joined Delos Capital in 2022 as the Executive Assistant for the firm's Hong Kong office. She previously worked as a secretary in the Corporate Legal Department at Nan Fung Group. She holds a Bachelor's in English for Professional Communications from City University of Hong Kong.

Carrie Greenaway· Office Operations, Boston Office· Bostonin

Carrie Greenaway joined Delos Capital in June 2024 and manages office operations for the firm's Boston office. She has over 15 years of operations experience spanning small startups to venture capital, most recently serving as Director of Finance and Operations at a Santa Monica-based event technology company. She holds a B.A. in International Relations from Saint Anselm College.

Paul Shen· Operations Manager· New Taipei City, New Taipei City, Taiwanin

Paul Shen joined Delos in 2022 as an Operations Manager. Before that, he spent 16 years working as an instructor and educator at five secondary schools and various test preparation centers. He holds a Bachelor of Arts from National Chung Hsing University and completed law extension courses at National Taiwan University.

Wynne Chan· Office Manager, Hong Kong Office· Hong Kongin

Wynne Chan is the Office Manager for Delos Capital's Hong Kong office, a role she has held since joining the firm in 2015. Before Delos Capital, she spent six years as Office Manager/Executive Assistant at Permira Advisers Limited and 14 years as an Executive Secretary in the Investment Banking Division of Goldman Sachs (Asia).

Hank Huang· Associate

h•••@deloscapital.comreveal

Yang Cheng· Associate, Ph.D.· Hong Kong, Hong Kong SARin

Yang Cheng joined Delos in 2022 as an Associate, bringing over ten years of experience in biomedical sciences. She was previously a drug discovery researcher at Boehringer Ingelheim focused on autoimmune diseases, holds a Ph.D. in Genetics from the University of Rochester, and a B.S. in Biology from Xiamen University.

y•••@deloscapital.comreveal

What they invest in

from 25 of 36 portfolio companies

Biotech ×19Healthtech ×19Medical Devices ×15Deep Tech ×4AI & Machine Learning ×2Digital Health ×2Hardware ×2Advanced Manufacturing ×1

HQs:United States×16Canada×1Singapore×1

Who they back

founder profiles across 12 portfolio companies

50%

solo founders

6 of 12 mapped founding teams

Founding team size:solo founder×62 founders×43 founders×14+ founders×1

Investments · 36 tracked

founders shown can be your intro path

By year:2026 · 1 2024 · 1 2021 · 1 2020 · 1 2019 · 26 dated

Zenas Biopharmazenasbio.com inNASDAQ: ZBIO

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)

BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Co-investorsLongitude Capital New Enterprise Associates (NEA)Norwest Venture Partners Quan Capital SR One Capital Management Vivo Capital +1 more

Siriusrnasiriusrna.com✓ verified

Sirius is a biotech company developing RNAi-based therapies focused on cardiovascular diseases for global markets.

BiotechHealthtech

Co-investorsOrbiMed Creacion Ventures

Tulavi Therapeuticstulavi.com in✓ verified

Tulavi develops medical devices for peripheral nerve surgery, aiming to improve surgical treatment options and patient outcomes in nerve care.

HardwareHealthtechMedical DevicesMountain View, US

Farhad Khosravi(Executive Officer, Director)Fred Khosravi(Chairman & Co-Founder)Josh Vose(Chief Executive Officer)Corinne Bright(Executive Officer, Director)

BoardHenry Chen(Director)in

Co-investorsAscension Ventures

Verge Medical Aorto-ostial interventional technologiesostialflash.com✓ verified

Verge Medical (formerly Ostial Corporation) develops medical devices for aorto-ostial vascular interventions, including the FLASH Flex aorto-ostial angioplasty system and the RoVo mechanical thrombectomy device, used by physicians for coronary and peripheral vascular cases.

HealthtechMedical Devices

Mike Buck(Chief Executive Officer)Adam Tschida(General Manager & COO)

Co-investorsAmed Ventures

▶︎ STRM.BIOstrm.bio in

STRM.BIO develops a gene therapy delivery platform based on megakaryocyte-derived extracellular vesicles (STRM MVs) that target and deliver genetic cargoes preferentially to bone marrow and hematopoietic stem cells.

BiotechDeep TechMedical Devices

Co-investorsAscension Ventures Breakout Labs Breakout Ventures NYBC Ventures KdT Ventures

Allecra Therapeutics GmbHallecra.com

Co-investorsAndera Partners BioMedPartners

Alpha-9 Oncologya9oncology.com inOct 2024

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen Horowitz General Catalyst Lightspeed Venture Partners Longitude Capital Lumira Ventures Nextech Invest +8 more

AltruBioaltrubio.com

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.

BiotechHealthtech

Co-investorsaMoon RA Capital

Antios

Novel antiviral therapies with a lead program in HBV

Apama

Ablation catheter for the untreated atrial fibrillation market (acquired)

Apbioincapbioinc.com

Atia Accommodating intraocular lens replacementatiavision.com in

Atia Vision develops OmniVu, a modular shape-changing dual-optic intraocular lens (IOL) that uses the eye's natural accommodative mechanism to restore near, intermediate, and distance vision for cataract patients.

HardwareHealthtechMedical DevicesCampbell, US

Co-investorsAmed Ventures The Capital Partnership

Avenzoavenzotx.com in

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsForesite Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)OrbiMed Quan Capital +3 more

Avernatxavernatx.com in

Averna Therapeutics is a biotechnology company developing therapeutics.

BiotechDeep TechMedical Devices

Thomas M. Barnes(CEO & Board Member)

Co-investorsDeep Insight Novartis Venture Fund OrbiMed

Baronovabaronova.com

Non-surgical, non-pharmacologic devices to induce weight loss

Co-investorsLongitude Capital

Cardurioncardurion.com in

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

Michael E. Mendelsohn(Founder and Chief Strategy Officer)Michael Mendelsohn, M.D.(Founder)in

Co-investorsBain Capital Digitalis Ventures New Enterprise Associates (NEA)

Cloverbiopharmacloverbiopharma.com in 𝕏Mar 2026

Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities.

BiotechHealthtechChengdu

Peng Liang(Executive Officer, Director, Promoter)Joshua Liang(Executive Officer, Director)

BoardXiaodong Wang(Director)

Curamir Therapeuticscuramirtherapeutics.comAug 2019

Woburn, US

LAN BO CHEN(Executive Officer, Director)BRYAN KEANEY(Executive Officer)

BoardHENRY CHEN(Executive Officer, Director)in

Curatia Interventional vascular productscuratiamed.com

Curatia Medical develops, manufactures, and sells single-use interventional disposables for cardiac, peripheral, neuro, and pulmonary procedures, serving cardiovascular professionals and OEM customers.

Advanced ManufacturingHealthtechMedical DevicesSunnyvale, US

Eccogeneeccogene.com in

Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease.

BiotechHealthtechCambridge, US

Ensomaensoma.com

Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.

BiotechHealthtechMedical DevicesBoston, US

Co-investors5AM Ventures Aju IB Invesment Corporation Catalio Capital Management, LP F-Prime Capital Solasta Ventures Bioluminescence Ventures

Hemocorphemocorp.com in

Hemo Group develops interventional medical devices for treating neuro-vascular diseases, including ischemic stroke, hemorrhagic stroke, and neuro access, with products such as the Afentta intracranial thrombectomy device.

BiotechHealthtechMedical DevicesSingapore, SG

Imperative Care Incimperativecare.com in 𝕏

Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.

HealthtechMedical DevicesCampbell, US

Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)Charles Alpuche(Executive Officer)Scott Elliott(Executive Officer)

BoardJames Rogers(Director)Stacy Enxing Seng(Director)

Co-investorsAscension Ventures FemHealth Ventures Lightstone Ventures

Instylla Incinstylla.com in 𝕏

Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels.

BiotechHealthtechMedical DevicesBedford, US

Amarpreet Sawhney(Executive Officer)Raymond Lareau(Executive Officer)Steven Cagnetta(Executive Officer)Sean Boyle(Chief Executive Officer)

BoardHenry Chen(Director)inTasneem Dohadwala(Director)in

Co-investorsAngel Physicians Fund Ascension Ventures Excelestar Ventures

Intrinsic Therapeuticsbarricaid.com in 𝕏

Barricaid develops a bone-anchored implant designed to reduce reherniation and reoperation in patients undergoing discectomy for large annular defects.

HealthtechMedical DevicesWoburn, US

Gregory H. Lambrecht(Director)Carey Hagan(Executive Officer, Director)Kevin Connors(Director)Cary Hagan(Executive Officer, Director)

BoardRyan Drant(Director)inJeani Delagardelle(Director)

Co-investorsNew Enterprise Associates (NEA)Questa Capital Greenspring Associates New Leaf Venture Partners

Liposeuticalsliposeuticals.com

Liposeuticals is a specialty pharmaceuticals company that reformulates sterile injectable drugs using a proprietary platform.

BiotechMedical Devices

Luqa

Specialty pharma in dermatology and aesthetics for the Chinese market (acquired)

Phanestheraphanesthera.com

Phanes Therapeutics is a clinical-stage biotech company developing bispecific antibodies and other biologics for immuno-oncology, with three Phase 2 trials (spevatamig, peluntamig, mavrostobart).

BiotechDeep TechHealthtech

Rejonirejoni.com inSep 2020

Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.

BiotechFemTechHealthtechMedical DevicesBedford, US

AMARPREET SAWHNEY(Executive Officer, Director, Promoter)inAmar Sawhney(Founder)NICK SVENCER(Executive Officer, Director, Promoter)FARHAD KHOSRAVI(Executive Officer, Director, Promoter)

BoardTARA BUTLER(Executive Officer, Director, Promoter)

Co-investorsAscension Ventures ClavystBio FemHealth Ventures Iyengar Capital Partners Amed Ventures Catalyst Health Ventures

Reniva

Therapeutic option to treat functional and degenerative mitral diseases

PartnerTim Xiao· led

Rgenta Therapeuticsrgentatx.com inNov 2021

Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Travis Wager(Co-founder, President and CSO)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)Simon Xi(Co-founder and CEO)Jackie Walling(CMO)Debasish Roychowdhury(Director)

Co-investorsVivo Capital AMR Action Fund Korea Investment Partners Lilly Asia Ventures

Syndaxsyndax.com

Co-investorsAisling Capital Avoro Capital Advisors BioBrit EcoR1 Capital

Tanvextanvex.com

ThermalinMay 2019

Developer of next-generation insulin solutions

BiotechWaban, US

Richard Berenson(Executive Officer, Director, Promoter)David C. Sweeney(Director)

BoardTim Xiao(Director)inJohn Brooks(Mr. Brooks is the Chairman of the Board of Directors.)

Trextrex.bio in

TRexBio develops Treg-focused biologic therapeutics for autoimmune and inflammatory diseases, using its Deep Biology Platform to analyze regulatory T cell behavior in human tissues and identify therapeutic targets.

AI & Machine LearningBiotechHealthtech

Co-investorsAvego BioScience Capital Pfizer Venture Investments Agent Capital

Truvictruvic.com

Co-investorsAscension Ventures

Exits · 1

IPOs and acquisitions across the tracked portfolio

Zenas BiopharmaNASDAQ: ZBIO

Portfolio news

latest coverage across their companies

Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy

Ensoma · fiercebiotech.com · Aug 7, 2026

Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWire

Avenzo · geekwire.com · Jul 13, 2026

Rejoni Raises $25M to Prepare Uterine Healing Hydrogel for FDA Approval and Launch | Femtech Insider

Rejoni · femtechinsider.com · Jul 1, 2026

Intrinsic Therapeutics Announces Initial Release of Its Next Generation Barricaid Narrow Anchor Device Designed to Reduce Reherniation After Back Surgery

Intrinsic Therapeutics · prnewswire.com · Mar 4, 2026

Frequently asked questions

How many investments has Delos Capital made?: Delos Capital has 36 tracked investments, including 2 dated in the last 24 months.
What stage does Delos Capital invest at?: Delos Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Delos Capital focus on?: Delos Capital focuses on Biotech, Healthtech, Medical Devices.
Where is Delos Capital located?: Delos Capital is headquartered in Cambridge, US.
Who does Delos Capital co-invest with?: Delos Capital most often shares deals with Ascension Ventures, New Enterprise Associates (NEA), Longitude Capital, among 45 tracked co-investors.

Images

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Korea Investment Partners

Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.

$973K – $50M